Navigation Links
FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Date:9/22/2007

nsion add to a growing body of evidence about the effectiveness of Campath across the entire B-CLL treatment pathway," stated Mark Enyedy, president of Genzyme's oncology business unit. "A broader range of patients is now eligible for Campath treatment, regardless of whether they have received prior therapy. The approval also marks an important step in a long-term development plan that is exploring the full potential of Campath in high-risk CLL, combination and consolidation therapy."

Presented at the 48th Annual Meeting of the American Society of Hematology (ASH) conference last year, data supporting the sBLA were part of an international Phase III clinical trial comparing Campath with chlorambucil in previously untreated patients with B-CLL. The study met its primary endpoint by demonstrating longer progression free survival (PFS) in patients treated with Campath versus chlorambucil, with Campath reducing the risk of disease progression or death by 42 percent (p=0.0001).

Patients receiving Campath exhibited higher overall and complete response rates that were statistically significant in comparison to patients who were treated with chlorambucil. Campath also demonstrated a manageable safety profile among study patients.

"We are excited that Campath can now be used to treat patients in the U.S. earlier in the course of their disease," said Gunnar Riemann, Ph.D., member of the Board of Management of Bayer Schering Pharma AG. "The ability to now provide Campath as a first-line treatment of the disease will make an important difference in battling B-CLL. It may help patients by offering a potentially more effective treatment approach that can extend progression-free survival."

Campath is marketed in the U.S. by Bayer HealthCare Pharmaceuticals Inc., as Campath, and outside the United States as MabCampath(R).

About B-Cell Chronic Lymphocytic Leukemia

According to the Leukemia and Lymphoma Society, approximately 15,000 new cases of B-
'/>"/>

SOURCE Genzyme Corp. and Bayer HealthCare Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. FDA approves Phase 0 trial which tests experimental drugs on humans
2. FDA Approves Contraceptive Ring
3. FDA approves new device to treat womens bleeding disorder
4. FDA Approves New HIV Drug, Viread
5. FDA Approves Birth Control Skin Patch
6. FDA approves surgical gel
7. FDA Approves New Arthritis Drug, Bextra
8. FDA Approves Elidel Cream for Eczema
9. FDA approves drug for rare liver disease
10. FDA approves first pocket-sized EKG machine
11. FDA Approves New Anti-Clotting Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Gainesville, FL (PRWEB) July 29, 2014 Many ... very first thing they do each morning is put on ... the bathroom. These same individuals also may be dissatisfied ... cataracts. , Cataracts may cause difficulty driving, especially ... harder to follow or find one’s golf ball, see the ...
(Date:7/29/2014)... LA (PRWEB) July 29, 2014 Historically, ... across the United States usually celebrated throughout that time ... though, those summer days now mark the start of ... crashes involving teen drivers. In 2012 nearly 1.000 ... the period from Memorial Day to Labor Day. , ...
(Date:7/29/2014)... 2014 Avenidas is always looking ... Once again, the non-profit agency is doing just that with ... seniors. , This event gives seniors the opportunity to learn ... There will be a variety of fun activities, including a ... demonstrations and artists. In addition, there will be food tastings, ...
(Date:7/29/2014)... 29, 2014 Summer is here, and that means ... a hike, swimming in a pool or laying out on the ... and ticks. The Puppy Store is here to help pet owners ... , It’s almost impossible to completely keep fleas and ticks at ... the chances of their pets coming into contact with fleas and ...
(Date:7/29/2014)... helps headache sufferers to record the severity and regularity ... a Griffith research study. , A new approach to ... coping with their triggers and is being led by ... of Health program. , He has developed an approach ... of their headaches called Learning to Cope with Triggers ...
Breaking Medicine News(10 mins):Health News:Cataract Surgery: New Technology for Reduced Dependence on Glasses 2Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2Health News:Protect Dogs From Fleas and Ticks During the Summer 2
... in four teenagers who had meningitis during infancy will not ... in Archives of Disease in Childhood. ,The findings ... year olds across England and Wales, 461 of whom had ... ,The children were all taking part in a long ...
... Scientists of University College London have conducted a study ... is indeed responsible// for dyscalculia or in ... hope the findings will aid in the diagnosis and ... ,Dyscalculia is just as prevalent in the population as ...
... the Victorian disease tuberculosis is on the march. Figures released by ... percent in number of TB cases over the last year. ... on the 24th of March, are provisional and relate ... account for the highest proportion of cases (42 percent) but the ...
... Steriani Elavsky, women passing through their menopause are reported to ... improvements in heart and respiratory fitness are said to have ... ,This research was carried out on 164 inactive menopausal ... basis. One group was assigned to perform Yoga while the ...
... junior doctors' has been reduced in order to increase their ... medics found that cutting down working hours alone is not ... of rotas was essential. ,The Occupational and Environmental ... Auckland universities in New Zealand. ,In the UK, ...
... that the odds of firefighters dying from coronary heart disease ... 100 times higher than during non-emergency duties such as rescuing ... Harvard Medical School and colleagues say episodic physical and psychological ... of physical fitness appeared responsible for it. ,Even though ...
Cached Medicine News:Health News:Reason Behind Dyscalculia Revealed 2Health News:TB Cases on the Rise 2Health News:Rest for Doctors to Ensure Patients’ Safet 2Health News:New Study Reveals That Firefighters Are Prone To Heart Attack 2
(Date:7/29/2014)...  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... conferences during the third quarter, the 2014 Avondale Partners ... 2014 Conference.  Alexza,s corporate presentation will be webcast live ... event are below: , 2014 Avondale Partners ... Boston , MA.  The format is limited ...
(Date:7/29/2014)... ROCKVILLE, Md. , July 29, 2014  Synthetic ... anti-infective biologic and drug candidates targeting specific pathogens that ... view of the unusual market activity in the Company,s ... Company in accordance with its usual practice. The Company ... unusual market activity. About Synthetic Biologics, Inc. ...
(Date:7/29/2014)... Conn. , July 29, 2014 Numotion,s Board ... Mike Swinford will be the company,s new Chief ... highly successful 22-year career at GE where he worked primarily ... in annual revenue to over $5 billion. His most recent ... Services. "I am thrilled to join Numotion," ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2Numotion Names Mike Swinford CEO 2
Kevorkian Collector Endocervical Curette is a stainless-steel curette with rounded tip....
Available in 5, 8 and 12 mm bite, with and without teeth....
...
...
Medicine Products: